Is the future equity common or preferred, and are you all planning on remaining an LLC for tax purposes prior to any IPO?

The future equity is preferred. It would be an LLC currently and we plan on remaining an LLC until we go public, for tax purposes as you say. When we go public we would become a C corporation and your equity would be preferred stock, and I would like to take the company public.

Hello, how many people participated in the clinical trials to date?

43 in Phase 1, 29 of whom got real drug and the rest placebo. 32 in a mechanism of action clinical trial got real drug. 143 in Phase 2, of whom 2/3 got real drug. In total about 150 people have been dosed with SQX770.

Could you explain your valuation?

Hi Nelson, it's Joe Cunningham, Squarex's CFO please note the following DCF calculations. Please know we look at the valuation from a number of different perspectives. We use various methods including a discounted cash flow and comparative marginal analysis. Ultimately it's a function of demographics. 15% of the adult population has 1 or more cold sore outbreaks each year, and 2.1% has 6 or more per year. Approximately 3-4%, therefore, have 4 or more outbreaks per year. The condition is about...

Hello. Is the finished product envisioned to be applied by a physician or would it be in-home use by the patient themselves?

It will be applied by the patient at home. It would be sold like an ordinary prescription drug, picked up at the pharmacy, and applied at home. That is more convenient for patients and better for our business than if it were sold and applied at physicians' offices.

When will this product be available for public use?

That depends on fundraising. If we are successful in this raise and raising the investment money we need to complete the Phase 3 trials, it could be available in as soon as 2 years.

Squarex, LLC Updates, Team, and Funding Progress | Wefunder, Home of the Community Round

Successfully completed Phase 2 clinical trials with clear path to commercialization

A single topical dose to the arm prevents outbreaks for over 4 months

Clinical trials conducted at Harvard and Stanford

Raised $5.75M in initial seed round

Global Oral Herpes Market projected $1.29B by 2028

Cofounded by former Executive Director of the American Board of Dermatology

Squarex, LLC

Preventing oral herpes with a topical application to the arm

$235,067

Updates

Squarex, LLC

Quick facts

Team profiles

Featured investor profiles

$235,067

Updates